Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Ampio reports preliminary findings from biochemical analysis from SPRING study

Feb. 14, 2014

Alvogen launches biosimilar monoclonal antibody therapy in Central and Eastern Europe

Feb. 13, 2014

Novel PADI4 inhibitors synthesized at GlaxoSmithKline

Feb. 13, 2014

Biogen Idec patent divulges novel S1P modulating agents

Feb. 11, 2014

GlaxoSmithKline reports discovery of selective androgen receptor modulators

Feb. 11, 2014

Protalex reports data from phase Ib trial of PRTX-100 in active rheumatoid arthritis

Feb. 11, 2014

Audentes and Genethon enter agreement to develop gene therapy for X-linked myotubular myopathy

Feb. 7, 2014

Mesoblast reports positive outcomes from phase II trial on back pain

Jan. 30, 2014

Seikagaku files for Japanese approval of SI-6603 for treatment of lumbar disc herniation

Jan. 30, 2014

Ares Trading, a subsidiary of Merck Serono, patents new IRAK-4 inhibitors

Jan. 30, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...